Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2016 Oct:120:56-64.
doi: 10.1016/j.diabres.2016.07.004. Epub 2016 Jul 30.

The effect of a brief action planning intervention on adherence to double-blind study medication, compared to a standard trial protocol, in the Atorvastatin in Factorial with Omega EE90 Risk Reduction in Diabetes (AFORRD) clinical trial: A cluster randomised sub-study

Affiliations
Randomized Controlled Trial

The effect of a brief action planning intervention on adherence to double-blind study medication, compared to a standard trial protocol, in the Atorvastatin in Factorial with Omega EE90 Risk Reduction in Diabetes (AFORRD) clinical trial: A cluster randomised sub-study

Andrew J Farmer et al. Diabetes Res Clin Pract. 2016 Oct.

Abstract

Aims: Clinical trial patients are highly motivated but may encounter difficulty in taking study medication regularly when treatment burden is substantial. We assessed a brief behavioural intervention, given in addition to a standard trial protocol.

Methods: We performed a two-arm adherence sub-study within a twelve-month randomised controlled drug trial evaluating the impact of statin and/or omega-3 EE90 treatment in 800 patients with type 2 diabetes. Fifty-nine United Kingdom general practices were cluster-randomised to action-planning or control groups. The former delivered an initial written exercise prompting participants to formulate action-plans to take study medication regularly, with brief nurse encouragement to use action-plans at later visits, whilst the latter followed the standard trial protocol. The primary outcome was proportion of days on which study medication were taken as intended measured by electronic medication containers.

Results: Adjusted mean (95% CI) proportion of days with medication taken as intended was 79.3% (76.3-82.3%)for the 30 action-planning practices (321 participants), compared with 78.5% (75.8-81.1%) for 27 control group practices (426 participants, with a mean intervention effect of 0.9%, 95% CI -3.1% to +4.9%, p=0.67). Adjusted odds ratios for ⩾80% trial medication adherence for action-planning compared with control practices were 1.29 (0.90-1.84) and 1.38 (0.96-1.99) respectively.

Conclusions: Low-intensity action-planning interventions used alone are unlikely to have a clinically important impact on medication adherence, particularly in a clinical trial setting. These findings, do not exclude their contribution, as part of a multifactorial intervention, to improving treatment adherence. ISRCTN number 76737502.

Keywords: Action planning; Adherence; Adults; Omega-3 EE90; Statin; Type 2 diabetes.

PubMed Disclaimer

Conflict of interest statement

Declarations of duality of interest.

RRH declares research funding from Bayer, Astra Zeneca, Merck and honoraria from Amgen, Bayer, Elcelyx, Jannsen, Intarcia, Merck, Novartis, and Novo Nordisk WH has done consultancy work for AbbVie Ltd. All other authors confirm that they have no dualities of interest.

Figures

Figure 1
Figure 1
Participant Flow Diagram
Figure 2
Figure 2
Proportion of trial participants in the action-planning and control groups taking their tablet and capsule streams of study medication. Reported by day of study. Footnote for Figure 2. Difference in adherence between the active and control groups, (P (trend) < 0.001)

Similar articles

Cited by

References

    1. International Diabetes Federation. IDF Diabetes Atlas. 7th Edition. Brussels, Belgium: 2015.
    1. Yach D, Stuckler D, Brownell K. Epidemiologic and economic consequences of the global epidemics of obesity and diabetes. Nat Med. 2006;12:62–6. - PubMed
    1. Colhoun H, Betteridge D, Durrington P, et al. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet. 2004;364:685–96. - PubMed
    1. Barber N. Should we consider non-compliance a medical error? Qual Saf Health Care. 2002;11:81–4. - PMC - PubMed
    1. Sheeran P, Orbell S. Implementation intentions and repeated behaviour: augmenting the predictive validity of the theory of planned behaviour. Eur J Soc Psychol. 1999;29:349–69.

Publication types

Substances